Vascular and Visual Emergencies

Suspected vascular compromise, visual disturbance, or stroke-like symptoms after injection are time-critical emergencies. Stop injecting, activate the established emergency pathway, and arrange immediate specialist transfer. Office measures must not delay emergency assessment.

This page supports recognition and preparedness. It is not a substitute for accredited complication training, a locally approved emergency protocol, or ophthalmic, stroke, and emergency services.

Recognize the signal

Domain	Concerning findings
Skin perfusion	Blanching, livedoid or reticulated change, dusky color, delayed capillary refill, progressive pain or sensory change
Vision	Sudden blur, field loss, partial or complete loss of vision
Ocular or periocular	Ocular pain, diplopia, ptosis, abnormal eye movement
Neurologic	Sudden weakness, speech change, confusion, severe headache, nausea or vomiting, other focal deficit
Time course	Immediate is typical, but evolving or delayed skin findings still require urgent assessment

Absence of one classic sign does not exclude compromise. Visual disturbance may occur with or without preceding skin change.

First priorities

Stop the injection and note the exact time.
Call the local emergency pathway for immediate transfer when visual or neurologic involvement is suspected.
Keep the patient accompanied and monitored within the clinician’s competence.
Communicate the suspected iatrogenic vascular event to the receiving service.
Do not allow office-based maneuvers to delay transfer.

Recent UK multidisciplinary consensus recommends immediate transfer to the closest emergency department for suspected ophthalmic or cerebrovascular involvement and advises practices to know the local emergency destination in advance (UK consensus 🔗). A separate review likewise emphasizes urgent transfer to a center capable of ophthalmic and neurologic assessment (vision-loss review 🔗).

Prepare a concise handover

Send or carry:

patient identifiers, relevant history, allergies, and current medicines
exact product, material, presentation, lot, and expiry
diluent, additions, and final preparation when relevant
injection time, anatomical site, side, documented plane, device, and amount
first symptom, exact onset, progression, and observations
actions already taken and response
current product information and safety document when available

Use documentation and follow-up to make these fields available before an emergency occurs.

Product-specific limits

Hyaluronidase protocols are designed around HA. They do not dissolve PLLA, PDLLA, CaHA, or PCL. In a hybrid formulation, affecting an HA component does not establish removal of the particulate component.

No universal office intervention has been shown to reliably reverse filler-induced visual loss. The current evidence is largely case-based and consensus-driven, which is why rapid specialist transfer takes priority.

The FDA identifies unintended intravascular injection as the most concerning filler risk and lists tissue necrosis, visual abnormalities including blindness, and stroke among reported outcomes (FDA dermal-filler safety information 🔗).

Readiness before the first injection

The practice should define and rehearse:

who stops treatment, calls emergency services, documents, and accompanies the patient
the nearest appropriate emergency, stroke, and ophthalmic route
communication with the receiving service
the locally authorized emergency kit and protocol
after-hours contact and escalation
post-event documentation, disclosure, follow-up, and regulatory reporting

Readiness is a clinic system, not an improvisation after symptoms begin.